autologous cord blood cell therapy

Autologous cord blood cell therapy is an investigational cell-based biologic developed by the Neonatal Encephalopathy Consortium, Japan, for the treatment of neonatal hypoxic-ischemic encephalopathy (HIE). The therapy involves the intravenous infusion of the patient's own volume-reduced, non-cryopreserved umbilical cord blood cells, which contain a variety of cell types including CD34+ hematopoietic stem cells. Administered in three doses within the first 72 hours of life, typically alongside therapeutic hypothermia, the treatment aims to mitigate brain injury by reducing apoptosis and oxidative stress while promoting neuroregenerative processes. Clinical trials, including a pilot safety study (NCT02256618), have demonstrated the feasibility and safety of this approach in newborns.

Other names

autologous umbilical cord blood cell therapyUCBC therapy